AI Accelerates Drug Discovery in Novo Nordisk's Partnership

Novo Nordisk partners with OpenAI for AI in drug discovery, manufacturing, and commercial ops.
Pilot programs start immediately; full integration by 2026.
OpenAI trains global workforce to boost AI literacy.
CEO Mike Doustdar aims to supercharge employees, not replace them, to improve productivity.
OpenAI CEO Sam Altman highlights AI's role in accelerating scientific discovery.
Experts caution AI has not yet mastered drug development's 'holy grail'.

Partnership | Drug Development | AI

United States | Denmark

Sam Altman | Mike Doustdar

3 days ago